Foresite Capital Fund IV, L.P. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 2:24 pm Sale | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund IV, L.P. | 0 0.000% | -4,066,277 (Position Closed) | Filing |
| 2023-02-13 5:06 pm Purchase | 2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund IV, L.P. | 4,066,277 6.100% | 4,066,277 (New Position) | Filing |